EUR 0.64
(-6.16%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 13.22 Million EUR | -22.47% |
2022 | 17.06 Million EUR | 13.47% |
2021 | 15.03 Million EUR | 57.85% |
2020 | 9.52 Million EUR | -61.72% |
2019 | 24.88 Million EUR | 317.68% |
2018 | 5.95 Million EUR | 55.06% |
2017 | 3.84 Million EUR | 17.86% |
2016 | 3.25 Million EUR | -11.91% |
2015 | 3.7 Million EUR | 47.11% |
2014 | 2.51 Million EUR | 7.83% |
2013 | 2.33 Million EUR | 561.52% |
2012 | 352.6 Thousand EUR | 67.5% |
2011 | 210.51 Thousand EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 18.06 Million EUR | 0.0% |
2023 Q4 | 13.22 Million EUR | 0.0% |
2023 Q2 | 17.67 Million EUR | 0.0% |
2023 FY | 13.22 Million EUR | -22.47% |
2022 Q4 | 17.06 Million EUR | 0.0% |
2022 Q2 | 16.81 Million EUR | 0.0% |
2022 FY | 17.06 Million EUR | 13.47% |
2021 Q4 | 15.03 Million EUR | 0.0% |
2021 FY | 15.03 Million EUR | 57.85% |
2021 Q2 | 9.67 Million EUR | 0.0% |
2020 Q2 | 5.6 Million EUR | 0.0% |
2020 FY | 9.52 Million EUR | -61.72% |
2020 Q4 | 9.52 Million EUR | 0.0% |
2019 Q2 | 26.72 Million EUR | 0.0% |
2019 Q4 | 24.88 Million EUR | 0.0% |
2019 FY | 24.88 Million EUR | 317.68% |
2018 FY | 5.95 Million EUR | 55.06% |
2018 Q2 | 3.96 Million EUR | 0.0% |
2018 Q4 | 5.95 Million EUR | 0.0% |
2017 Q2 | 8.05 Million EUR | 0.0% |
2017 FY | 3.84 Million EUR | 17.86% |
2017 Q4 | 3.84 Million EUR | 0.0% |
2016 Q2 | 1.62 Million EUR | 0.0% |
2016 Q4 | 3.25 Million EUR | 0.0% |
2016 FY | 3.25 Million EUR | -11.91% |
2015 FY | 3.7 Million EUR | 47.11% |
2015 Q4 | 3.7 Million EUR | 0.0% |
2015 Q2 | 2.33 Million EUR | 0.0% |
2014 FY | 2.51 Million EUR | 7.83% |
2014 Q4 | 2.51 Million EUR | 0.0% |
2013 FY | 2.33 Million EUR | 561.52% |
2012 FY | 352.6 Thousand EUR | 67.5% |
2011 FY | 210.51 Thousand EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -91.367% |
ABIVAX Société Anonyme | 131.05 Million EUR | 89.907% |
Adocia SA | 31.87 Million EUR | 58.496% |
Aelis Farma SA | 13.08 Million EUR | -1.126% |
Biophytis S.A. | 15.84 Million EUR | 16.542% |
Advicenne S.A. | 24.37 Million EUR | 45.739% |
genOway Société anonyme | 14.45 Million EUR | 8.522% |
IntegraGen SA | 5.97 Million EUR | -121.199% |
Medesis Pharma S.A. | 6.42 Million EUR | -105.834% |
Neovacs S.A. | 3.71 Million EUR | -256.326% |
NFL Biosciences SA | 3.62 Million EUR | -265.325% |
Plant Advanced Technologies SA | 6.78 Million EUR | -95.025% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -299.602% |
Theranexus Société Anonyme | 5.01 Million EUR | -163.692% |
TME Pharma N.V. | 2.78 Million EUR | -374.947% |
Valbiotis SA | 13.7 Million EUR | 3.507% |
TheraVet SA | 1.48 Million EUR | -790.729% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | 35.376% |
argenx SE | 402.79 Million EUR | 96.716% |
BioSenic S.A. | 32.26 Million EUR | 59.003% |
Celyad Oncology SA | 9.97 Million EUR | -32.564% |
DBV Technologies S.A. | 38.74 Million USD | 65.861% |
Galapagos NV | 1.56 Billion EUR | 99.153% |
Genfit S.A. | 105.92 Million EUR | 87.512% |
GeNeuro SA | 20.13 Million EUR | 34.323% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -53.591% |
Innate Pharma S.A. | 132.29 Million EUR | 90.001% |
Inventiva S.A. | 101.59 Million EUR | 86.98% |
MaaT Pharma SA | 22.46 Million EUR | 41.121% |
MedinCell S.A. | 77.77 Million EUR | 82.992% |
Nanobiotix S.A. | 95.74 Million EUR | 86.184% |
Onward Medical N.V. | 25.69 Million EUR | 48.528% |
Oryzon Genomics S.A. | 25.12 Million EUR | 47.355% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 77.611% |
Oxurion NV | 19.73 Million EUR | 32.979% |
Pharming Group N.V. | 228.28 Million EUR | 94.206% |
Poxel S.A. | 53.9 Million EUR | 75.46% |
GenSight Biologics S.A. | 34.72 Million EUR | 61.911% |
Transgene SA | 26.51 Million EUR | 50.118% |
Financière de Tubize SA | 123.65 Million EUR | 89.303% |
UCB SA | 6.56 Billion EUR | 99.798% |
Valneva SE | 341.14 Million EUR | 96.123% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -190.901% |